Novel Ruthenium coordinate compound combined with Schiff base and benzimidazole as a potent antibacterial agent against VRSA and MRSA

Abstract

The rise of antibiotic-resistant strains is an important public health problem and thus the development of an alternative to antibiotics is imminent. The Ruthenium–Schiff base with benzimidazole (RU–S2), a co-ordinate compound is novel and first of its kind to be synthesized in such combination. The aim of the experiment is based on the synthesis of RU–S2 and to study its antibacterial activity against the pathogenic resistant strains of Staphylococcus aureus like Vancomycin-resistant Staphylococcus aureus (VRSA) and Methicillin-resistant Staphylococcus aureus (MRSA). The antibacterial activity was studied using growth curve analysis based on turbidimetry which was confirmed by the fluorescence live/dead cell microscopic imaging of the bacteria after treatment with RU–S2. Lastly, the cytotoxicity test was performed by 3-(4,5-Dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT) assay against human normal and cancer epithelial cell lines to understand the toxic effects of RU-S2 at 160 µg/ml concentration. The concentration 160 µg/ml of RU–S2 was very effective against those resistant strains and also nontoxic in this concentration. Thus RU-S2 can be used as an efficient alternative to antibiotics that have promising antibacterial efficacy against the pathogenic strains with no toxicity and biocompatibility towards human cells.The rise of antibiotic-resistant strains is an important public health problem and thus the development of an alternative to antibiotics is imminent. The Ruthenium–Schiff base with benzimidazole (RU–S2), a co-ordinate compound is novel and first of its kind to be synthesized in such combination. The aim of the experiment is based on the synthesis of RU–S2 and to study its antibacterial activity against the pathogenic resistant strains of Staphylococcus aureus like Vancomycin-resistant Staphylococcus aureus (VRSA) and Methicillin-resistant Staphylococcus aureus (MRSA). The antibacterial activity was studied using growth curve analysis based on turbidimetry which was confirmed by the fluorescence live/dead cell microscopic imaging of the bacteria after treatment with RU–S2. Lastly, the cytotoxicity test was performed by 3-(4,5-Dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT) assay against human normal and cancer epithelial cell lines to understand the toxic effects of RU-S2 at 160 µg/ml concentration. The concentration 160 µg/ml of RU–S2 was very effective against those resistant strains and also nontoxic in this concentration. Thus RU-S2 can be used as an efficient alternative to antibiotics that have promising antibacterial efficacy against the pathogenic strains with no toxicity and biocompatibility towards human cells.